MorphoSys (MOR) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View MOR analyst ratings or view top-rated stocks.

9 brokers have issued 1-year price targets for MorphoSys' stock. Their MOR share price forecasts range from $9.25 to $17.00. On average, they expect the company's stock price to reach $12.81 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for MOR or view top-rated stocks among Wall Street analysts.

MorphoSys' stock was trading at $3.58 at the start of the year. Since then, MOR stock has increased by 120.7% and is now trading at $7.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our MOR earnings forecast.

MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $57.91 million for the quarter. MorphoSys had a net margin of 27.67% and a trailing twelve-month return on equity of 154.85%.

Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio.

5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

MorphoSys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Hudson Bay Capital Management LP (0.00%), Point72 Asset Management L.P. (0.00%), Marshall Wace LLP (0.14%), Tekla Capital Management LLC (0.13%), Wells Fargo & Company MN (0.00%) and Artia Global Partners LP (0.00%).

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MOR stock can currently be purchased for approximately $7.90.

MorphoSys (NASDAQ:MOR) has a market capitalization of $1.08 billion and generates $292.84 million in revenue each year. The company earns $-159,150,000.00 in net income (profit) each year or $0.43 on an earnings per share basis.

The company employs 544 workers across the globe.

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The official website for the company is www.morphosys.com. The company can be reached via phone at (498) 989-9270, via email at investors@morphosys.com, or via fax at 49-89-8992-7222.